BIIB Biogen Inc. Stock Quote

BIIB [NASD]

Healthcare | Drug Manufacturers - General | USA

Index	S&P 500	P/E	11.17	EPS (ttm)	24.45	Insider Own	0.10%	Shs Outstand	153.40M	Perf Week	-4.00%
Market Cap	42.29B	Forward P/E	13.39	EPS next Y	20.41	Insider Trans	1.64%	Shs Float	151.36M	Perf Month	2.00%
Income	4.00B	PEG	-	EPS next Q	5.04	Inst Own	87.50%	Short Float	2.26%	Perf Quarter	13.03%
Sales	13.44B	P/S	3.15	EPS this Y	-21.10%	Inst Trans	-1.59%	Short Ratio	2.65	Perf Half Y	-2.12%
Book/sh	69.75	P/B	3.92	EPS next Y	10.55%	ROA	15.80%	Target Price	291.37	Perf Year	-11.88%
Cash/sh	16.86	P/C	16.20	EPS next 5Y	-11.06%	ROE	35.30%	52W Range	223.25 - 363.92	Perf YTD	11.59%
Dividend	-	P/FCF	10.18	EPS past 5Y	10.10%	ROI	19.60%	52W High	-24.92%	Beta	0.44
Dividend %	-	Quick Ratio	1.60	Sales past 5Y	4.50%	Gross Margin	86.60%	52W Low	22.39%	ATR	8.17
Employees	9100	Current Ratio	1.80	Sales Q/Q	-22.30%	Oper. Margin	33.80%	RSI (14)	50.04	Volatility	3.05% 2.99%
Optionable	Yes	Debt/Eq	0.69	EPS Q/Q	-71.30%	Profit Margin	29.80%	Rel Volume	0.82	Prev Close	272.88
Shortable	Yes	LT Debt/Eq	0.69	Earnings	Feb 03 BMO	Payout	0.00%	Avg Volume	1.29M	Price	273.24
Recom	2.70	SMA20	-0.85%	SMA50	3.17%	SMA200	0.13%	Volume	1,060,208	Change	0.13%

Feb-05-21

Downgrade

DZ Bank

Buy → Hold

$264

Jan-29-21

Upgrade

Stifel

Hold → Buy

$258 → $358

Nov-10-20

Upgrade

DZ Bank

Hold → Buy

$265

Nov-09-20

Reiterated

H.C. Wainwright

Buy

$318 → $289

Nov-09-20

Downgrade

Cowen

Outperform → Market Perform

$215

Nov-09-20

Downgrade

BofA Securities

Neutral → Underperform

$240

Nov-09-20

Downgrade

Atlantic Equities

Neutral → Underweight

$175

Nov-04-20

Upgrade

Wells Fargo

Equal Weight → Overweight

$390

Nov-04-20

Upgrade

Jefferies

Hold → Buy

$450

Nov-04-20

Upgrade

BofA Securities

Underperform → Neutral

Oct-28-20

Initiated

UBS

Neutral

$268

Jul-27-20

Upgrade

Morgan Stanley

Underweight → Overweight

$263 → $357

Jun-22-20

Reiterated

RBC Capital Mkts

Sector Perform

$303 → $273

Jun-22-20

Downgrade

Barclays

Overweight → Equal Weight

$370 → $280

Jun-09-20

Downgrade

Bernstein

Outperform → Mkt Perform

$360 → $297

Apr-23-20

Downgrade

Raymond James

Mkt Perform → Underperform

Apr-23-20

Downgrade

Citigroup

Neutral → Sell

$365 → $240

Mar-31-20

Initiated

Wolfe Research

Peer Perform

Feb-27-20

Initiated

Barclays

Overweight

$389

Jan-27-20

Upgrade

Canaccord Genuity

Hold → Buy

$360

Mar-01-21 05:11PM	Denali's (DNLI) Q4 Earnings & Revenues Beat on Biogen Deal Zacks
Feb-26-21 01:16PM	7 Stocks to Sell for March InvestorPlace
Feb-24-21 04:28PM	10 Cheap Stocks To Invest In (February 2021) Insider Monkey
07:30AM	Life Science Cares and Biogen Foundation Help Launch Food For Frees Just Eats Program GlobeNewswire
06:53AM	Sage Therapeutics Rises After Swing to Profit on Biogen Deal TheStreet.com
Feb-23-21 06:30AM	Where Will Biogen Be in 5 Years? Motley Fool
Feb-20-21 06:12AM	Is Biogen Stock a Buy? Motley Fool
Feb-16-21 04:16PM	Cassava Stock Pops Again; Can It Take On Biogen In Alzheimer's Drugs? Investor's Business Daily
Feb-12-21 10:00AM	Eli Lilly Executives Enthusiastic About Alzheimers Drug, Analyst Says Barrons.com
09:23AM	Is the FDA Delay Actually Good News for Biogen's Alzheimer's Drug? Motley Fool
06:25AM	Why Is Everyone Talking About Biogen Stock? Motley Fool
Feb-11-21 04:23PM	This Dollar-Stock Biotech Popped In Bullish Volume On Its Alzheimer's News Investor's Business Daily
12:00PM	Why Alkermes' Q4 Results Were Better Than They Might Seem Motley Fool
09:13AM	The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte Zacks
08:03AM	Biogen Announces the Expiration Date Results of Its Cash Tender Offer GlobeNewswire
08:00AM	Biogen Announces the Expiration Date Results of Its Private Exchange Offer GlobeNewswire
07:30AM	Biogen and LabCentral Award Two Golden Tickets to Local and Innovative Science Startups GlobeNewswire
Feb-10-21 01:02PM	Biogen Announces the Pricing Terms of its Cash Tender Offer GlobeNewswire
01:00PM	Biogen Announces the Pricing Terms of Its Private Exchange Offer GlobeNewswire
11:57AM	Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates Zacks
Feb-09-21 06:27AM	Should You Sell Cassava Sciences Stock Now? Motley Fool
Feb-08-21 08:22AM	What to Know Before Buying Cassava Sciences, the Hot Alzheimers Stock Barrons.com
Feb-07-21 01:44PM	Biogens Alzheimers Drug Faces a Big Test. What to Know. Barrons.com
01:27PM	The Other Pandemic: What to Do About the Coming Alzheimers Crisis Barrons.com
Feb-06-21 01:52PM	Barron's Picks And Pans: Amazon, Biogen, Casey's General Stores, Hilton And More Benzinga
Feb-05-21 01:15AM	Have Insiders Been Buying Biogen Inc. (NASDAQ:BIIB) Shares? Simply Wall St.
Feb-04-21 04:10PM	10 Cheap Healthcare Stocks To Buy Now Insider Monkey
11:11AM	Biogen Inc. -- Moody's assign's Baa1 to Biogen's notes; on review for downgrade Moody's
09:10AM	Biogen: Debt Overview Benzinga
09:02AM	Biogen Announces Cash Tender Offer for 5.200% Senior Notes Due 2045 Open to Certain Holders Only GlobeNewswire
09:00AM	Biogen Announces Private Exchange Offer for 5.200% Senior Notes Due 2045 Open to Certain Investors GlobeNewswire
04:34AM	Biogens 4Q Earnings Miss Street Estimates; Shares Fall 5.2% SmarterAnalyst
Feb-03-21 04:40PM	Biogen Crumbles; Disappointing 2021 Outlook Calls For A 'Sharp Decline' Investor's Business Daily -5.21%
01:01PM	Biogen Inc (BIIB) Q4 2020 Earnings Call Transcript Motley Fool
12:52PM	Biogen (BIIB) Q4 Earnings Miss, Revenues Surpass Estimates Zacks
11:30AM	Why Biogen's Q4 Results Were a Bust Motley Fool
10:25AM	Biotech Stock Roundup: AMGN, VRTX Q4 Results, SAVA's Encouraging Drug Data & More Zacks
10:04AM	Biogen Stock Is Falling Because Earnings Guidance Came Up Short Barrons.com
08:39AM	Biogen Off on Weaker-Than-Expected 2021 Forecast TheStreet.com
08:35AM	Biogen Inc. (BIIB) Misses Q4 Earnings Estimates Zacks
08:21AM	Perrigo will not receive $400 million milestone payment MarketWatch
07:19AM	Biogen: Q4 Earnings Insights Benzinga
06:15AM	Biogen, Inc. to Host Earnings Call ACCESSWIRE
Feb-02-21 10:12AM	Preview: Biogen's Earnings Benzinga
Feb-01-21 09:40AM	Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4? Zacks
07:30AM	Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis GlobeNewswire
Jan-31-21 03:40AM	Biogen Shares Gain 5.5% As FDA Extends Review Period For Alzheimers Drug SmarterAnalyst
Jan-29-21 04:23PM	Biogen Surges To Two-Month High On Delayed Review For Alzheimer's Drug Investor's Business Daily +5.50%
01:52PM	Why Biogen Stock Popped Today Motley Fool
11:40AM	Biogen shares jump 9% after FDA extends review period for Alzheimer's treatment MarketWatch
11:16AM	Lilly Reports Strong Sales, Boosted by Covid Antibodies Barrons.com
10:38AM	The FDA Delayed Its Decision on Biogens Alzheimers Drug. The Stock Is Up 10%. Barrons.com
09:15AM	Biogen Shares Jump After FDA Delays Aducanumab Decision By 3 Months Benzinga
09:10AM	U.S. FDA extends review period for Biogen's Alzheimer's drug Reuters
07:41AM	U.S. FDA extends review period for Biogen's Alzheimer's drug to June Reuters
07:30AM	Biogen and Eisai Announce FDAs 3-Month Extension of Review Period for the Biologics License Application for Aducanumab GlobeNewswire
05:47AM	Biogen Analysts Laud FDA Extension of Alzheimer's Drug Review TheStreet.com
Jan-28-21 04:55PM	How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits? Investor's Business Daily
07:15AM	Is Biogen Stock A Buy After As Alzheimer's Drug Heads To Full FDA? Investor's Business Daily
Jan-27-21 12:10PM	Why the Earnings Surprise Streak Could Continue for Biogen Inc. (BIIB) Zacks
10:08AM	Vir Will Test Its Covid-19 Antibody With Eli Lillys, Sending Shares Up Again Barrons.com
06:50AM	2 Biotech Stocks With Major Potential Catalysts in 2021 Motley Fool
Jan-22-21 05:36AM	4 Stocks Warren Buffett Is Likeliest to Sell in 2021 Motley Fool
Jan-20-21 10:35AM	Eli Lilly Stock Is Surging on Hope for Alzheimers Drug. Analyst Says It Wont Last. Barrons.com
Jan-19-21 01:29PM	Top Healthcare Stocks for February 2021 Investopedia
Jan-15-21 10:39AM	The Zacks Analyst Blog Highlights: PayPal, Exxon Mobil, Goldman Sachs, Charter Communications and Biogen Zacks
Jan-14-21 03:29PM	Biogen Stock Is Jumping Because There May Be Hope for Its Alzheimers Drug Yet Barrons.com +5.11%
09:00AM	Prometheum Closes US $15M+ in Oversubscribed Funding Round CNW Group
Jan-13-21 09:35AM	Diamondback Energy, Ryman Hospitality Properties, Eli Lilly, Biogen and Roche highlighted as Zacks Bull and Bear of the Day Zacks
Jan-12-21 03:10PM	Eli Lilly Has Good News About Its Alzheimers Drug. Heres What It Means for Biogen. Barrons.com
12:10PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BIIB, PINS and KNDI ACCESSWIRE
11:00AM	BIIB Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 12, 2021 ACCESSWIRE
10:25AM	Lilly's (LLY) Alzheimer's Drug Promising in Mid-Stage Study Zacks
10:15AM	The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of BIIB, YY and OTGLY ACCESSWIRE
09:50AM	Apple (AAPL), Biogen to Track Cognitive Health via Wearables Zacks
09:14AM	DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm PR Newswire
08:56AM	Gilead, Biogen Lead Biotechs That Need to Do Deals for Growth Bloomberg
Jan-11-21 04:29PM	Lilly Rockets On Alzheimer's News And 3 Other Highlights From Key Health Care Meeting Investor's Business Daily +5.93%
02:01PM	BIIB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 12, 2021 in the Class Action Filed on Behalf of Biogen Inc. Limited Shareholders Newsfile
12:59PM	Lillys Alzheimer's Drug Isnt Worth $20 Billion Yet Bloomberg
12:33PM	BIIB FILING DEADLINE TOMORROW: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. GlobeNewswire
12:25PM	CLASS ACTION UPDATE for BIIB, BABA and NAK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:42AM	Biogen's stock is up 5% after Lilly reports positive data from an Alzheimer's study MarketWatch
11:00AM	DEADLINE ALERT for TILE, BABA, and BIIB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:00AM	BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 12, 2021 Newsfile
10:38AM	Apple Partners With Biogen On Research Into Detecting Early Alzheimer's, Dementia Symptoms Benzinga
09:28AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 12, 2021 - BIIB Newsfile
08:55AM	Eli Lilly Stock Gains as Drug Slows Decline in Alzheimers Patients Barrons.com
08:00AM	Portnoy Law: Lawsuit Filed On Behalf of Biogen, Inc. Investors GlobeNewswire
07:30AM	Biogen to Launch Pioneering Study to Develop Digital Biomarkers of Cognitive Health Using Apple Watch and iPhone GlobeNewswire
Jan-10-21 10:25AM	LAWSUITS FILED AGAINST BIIB, SPLK and QSR - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS ACCESSWIRE
Jan-09-21 02:02PM	DEADLINE FOR BIIB INVESTORS: Bernstein Liebhard LLP Reminds Investors That Only 3 Days Remain to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Biogen Inc. Newsfile
Jan-08-21 09:00PM	DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Biogen, Inc. and Encourages Investors to Contact the Firm GlobeNewswire
12:45PM	The Gross Law Firm Announces Class Actions on Behalf of Shareholders of BIIB, NAK and NERV ACCESSWIRE
12:00PM	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB) Business Wire
11:20AM	CLASS ACTION UPDATE for BIIB, BABA and QS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE
11:00AM	Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Biogen, Inc. (BIIB) PR Newswire
11:00AM	BIIB Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Biogen Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 12, 2021 Business Wire
09:07AM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 12, 2021 - BIIB Newsfile
07:30AM	Biogen Announces First Patient Treated in RESPOND Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated With Zolgensma® (onasemnogene abeparvovec) GlobeNewswire

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sandrock Alfred	EVP, Research & Development	Feb 12	Option Exercise	0.00	4,454	0	19,715	Feb 17 05:01 PM
Vounatsos Michel	Chief Executive Officer	Feb 12	Option Exercise	0.00	16,289	0	60,194	Feb 17 05:03 PM
Kramer Robin	SVP, Chief Accounting Officer	Feb 12	Option Exercise	0.00	333	0	706	Feb 17 04:59 PM
Guindo Chirfi	EVP Glob. Prod Strat and Comm	Feb 12	Option Exercise	0.00	3,156	0	6,946	Feb 17 04:58 PM
Gregory Ginger	EVP, Human Resources	Feb 12	Option Exercise	0.00	2,923	0	9,288	Feb 17 04:56 PM
Galdes Alphonse	EVP Pharmaceutical Oper & Tech	Feb 12	Option Exercise	0.00	1,573	0	4,765	Feb 17 04:54 PM
ALEXANDER SUSAN H	EVP Chief Legal Off & Corp Sec	Feb 12	Option Exercise	0.00	4,355	0	43,509	Feb 17 04:52 PM
Mantas Jesus B	Director	Feb 09	Buy	267.00	898	239,766	2,943	Feb 10 04:31 PM
Kramer Robin	VP, Chief Accounting Officer	Dec 03	Option Exercise	0.00	74	0	395	Dec 07 09:08 PM
Guindo Chirfi	EVP Glob. Prod Strat and Comm	Dec 01	Option Exercise	0.00	481	0	4,004	Dec 03 05:41 PM
Vounatsos Michel	Chief Executive Officer	Nov 30	Buy	241.31	3,100	748,047	34,810	Dec 01 04:57 PM
Sandrock Alfred	EVP, Research & Development	Nov 04	Sale	350.00	1,500	525,000	13,066	Nov 06 09:39 PM
Gregory Ginger	EVP, Human Resources	Jul 31	Option Exercise	0.00	212	0	4,786	Aug 04 04:12 PM
SHERWIN STEPHEN A	Director	Mar 11	Option Exercise	58.46	12,278	717,772	16,517	Mar 12 06:56 PM
SHERWIN STEPHEN A	Director	Mar 11	Sale	295.22	2,434	718,574	14,353	Mar 12 06:56 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience